


Biomunex unveils MAIT cell redirection approach for lead immune-oncology program at PEGS Boston Conference

AdBio partners welcomes Inserm Transfert as investor in second fund – AFB Fund II

Biomunex appoints Dr. Simon Plyte, PhD, as Chief Scientific Officer to boost clinical and business development

Ribonexus receives €2M in deep tech financing from Bpifrance

Seekyo adds diagnostics and theranostics capabilities to its lead compound SKY01 that targets solid tumors

AACR 2022: Tollys releases new preclinical data demonstrating lifelong potent anti-tumor immunity of TL-532

Nosopharm signs partnership with INRAE and University of Montpellier to develop new anti-infectives

SeaBeLife receives close to €1.4M deep tech financing from Bpifrance
